비교리스트

 카트 문의
시장보고서
상품코드
1479334

세계의 특발성 폐섬유증 시장

Idiopathic Pulmonary Fibrosis
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 181 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

특발성 폐섬유증 세계 시장, 2030년에는 61억 달러에 달할 전망

2023년에 42억 달러로 추정되는 특발성 폐섬유증 세계 시장은 2023년부터 2030년까지 CAGR 5.7%로 성장하여 2030년에는 61억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 피르페니돈 의약품은 CAGR 5.3%를 기록하고, 분석기간 종료시에는 43억 달러에 달할 것으로 예측됩니다. 닌테다닙 의약품 부문은 향후 7년간 CAGR이 6.6%로 추정됩니다.

미국 시장은 13억 달러, 중국은 CAGR 5.4%로 성장할 것으로 예측

미국의 특발성 폐섬유증 시장은 2023년에는 13억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2023년부터 2030년까지 분석기간 동안 CAGR 5.4%로 성장하여 2030년에는 시장 규모가 11억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지리적 시장으로는 일본과 캐나다가 있고, 각각 2023년부터 2030년까지 5.3%와 4.4%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 4.5%로 성장할 것으로 예측됩니다.

2024년에 새롭게 선보이는 흥미로운 보고서 기능 소개

인플루언서 참여 통계에 대한 풀 액세스

디지털 아카이브와 "MarketGlass" 조사 플랫폼에 무료로 액세스할 수 있습니다. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 도구는 시장 진입자의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 전망을 제공합니다. 보고서의 수치, 통계 및 시장 설명은 이 분야의 전문가와 영향력 있는 사람들이 공유한 완전히 선별된 인사이트를 기반으로 합니다.

실시간 데이터 시뮬레이터 도구와 맞춤형 보고서 작성 기능을 갖춘 인터랙티브 설문 조사에 참여할 수 있습니다.

기업 간 스마트한 의견 교환을 위한 피어 협업 인터랙티브 플랫폼에 대한 풀 클라이언트 액세스

1년간 무료 보고서 업데이트

주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지

여러 지역에 걸친 기업의 시장 입지 분석(호조/활발/틈새/마이너)

전문가/인플루언서 인터뷰, 팟캐스트, 언론 발표, 이벤트 기조연설 유튜브 동영상에 대한 접근성

2024년 세계 경제에 대한 기대

통화 긴축과 이에 따른 금리 상승으로 인한 지정학적, 경제적 불안정성이 2024년 격동적인 상황을 만들어 낼 것으로 보입니다. 중동의 적대 행위와 점점 더 잦아지는 기후 재해 등 여러 요인들이 회복의 길에 계속 압력을 가할 것으로 예상됩니다. 위험요인이 있는 반면, 디플레이션 조짐이 강해지고, 완고한 인플레이션에 대한 불안감이 완화되고, 공급망이 정상화되고, 에너지 비용 변동에도 불구하고 물가가 완만하게 상승하는 등 몇 가지 긍정적인 요인도 나타나고 있습니다. 인도와 미국을 비롯한 G21 국가들의 선거는 자본 흐름과 투자 전략에 영향을 미칠 수 있습니다. 인도가 글로벌 투자처로 주목받고 있는 가운데, 미국에 기반을 둔 하이테크 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속 우위를 점할 것으로 보입니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 둔화되긴 했지만 여전히 견고하고 규제 환경이 잘 정비되어 있어 높은 성장 잠재력을 추구하는 투자자들에게 여전히 매력적일 것으로 보입니다. 유럽은 긴축정책과 경기침체 리스크와의 싸움이 계속되고 있으며, 영국은 2024년 경기침체 리스크가 가장 높은 국가로 가장 어려운 전망을 보이고 있습니다. 중국은 정부 지출과 개인 소비 개선에 힘입어 성장세를 이어갈 것으로 예상되는 와일드카드가 될 것입니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 가져다 줄 것으로 보입니다. 변동성을 성장의 촉매제로 받아들이고, 민첩한 투자 판단과 전략적 선견지명이 생존을 위한 핵심 요소로 작용할 것입니다.

조사 대상 기업 사례(총 16건)

  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • ProMetic Life Sciences, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계 기타 지역

제4장 경쟁

KSM 24.05.21

Global Idiopathic Pulmonary Fibrosis Market to Reach $6.1 Billion by 2030

The global market for Idiopathic Pulmonary Fibrosis estimated at US$4.2 Billion in the year 2023, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 5.7% over the period 2023-2030. Pirfenidone Drug, one of the segments analyzed in the report, is expected to record 5.3% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Nintedanib Drug segment is estimated at 6.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 5.4% CAGR

The Idiopathic Pulmonary Fibrosis market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 16 Featured) -

  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Galapagos NV
  • MediciNova, Inc.
  • Merck & Co., Inc.
  • Promedior, Inc.
  • ProMetic Life Sciences, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Idiopathic Pulmonary Fibrosis - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for PIRFENIDONE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for NINTEDANIB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Idiopathic Pulmonary Fibrosis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • JAPAN
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • CHINA
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • EUROPE
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • FRANCE
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • GERMANY
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Idiopathic Pulmonary Fibrosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Idiopathic Pulmonary Fibrosis by Drug Type - PIRFENIDONE and NINTEDANIB Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Drug Type - Percentage Breakdown of Value Sales for PIRFENIDONE and NINTEDANIB for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Idiopathic Pulmonary Fibrosis by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제